Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PEN 
Penumbra Inc (PEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: PEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $318.62
1 Year Target Price $318.62
| 12 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.32% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.72B USD | Price to earnings Ratio 232.46 | 1Y Target Price 318.62 |
Price to earnings Ratio 232.46 | 1Y Target Price 318.62 | ||
Volume (30-day avg) 18 | Beta 0.49 | 52 Weeks Range 148.00 - 310.00 | Updated Date 07/4/2025 |
52 Weeks Range 148.00 - 310.00 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.41% | Operating Margin (TTM) 12.45% |
Management Effectiveness
Return on Assets (TTM) 5.82% | Return on Equity (TTM) 3.5% |
Valuation
Trailing PE 232.46 | Forward PE 70.42 | Enterprise Value 9564341496 | Price to Sales(TTM) 7.84 |
Enterprise Value 9564341496 | Price to Sales(TTM) 7.84 | ||
Enterprise Value to Revenue 7.71 | Enterprise Value to EBITDA 131.67 | Shares Outstanding 38725900 | Shares Floating 37577716 |
Shares Outstanding 38725900 | Shares Floating 37577716 | ||
Percent Insiders 3.61 | Percent Institutions 91.83 |
Upturn AI SWOT
Penumbra Inc
Company Overview
History and Background
Penumbra, Inc. was founded in 2004 by Adam Elsesser and Arani Bose. It's a global healthcare company focused on innovative therapies. Penumbra initially focused on neurovascular interventions and has expanded into peripheral vascular therapies.
Core Business Areas
- Neurovascular: Develops and markets products for treating stroke and other neurovascular diseases. These products focus on aspiration thrombectomy to remove clots from the brain.
- Peripheral Vascular: Offers a range of products for treating peripheral vascular diseases, including catheters, embolization coils, and thrombectomy systems.
Leadership and Structure
Adam Elsesser serves as the Chairman, President, and Chief Executive Officer. The company operates with a functional organizational structure, with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Penumbra System: Aspiration-based thrombectomy system for stroke treatment. Market share is estimated to be around 30% in the US aspiration thrombectomy market. Competitors include Medtronic and Stryker. Major revenue driver.
- Indigo System: Mechanical thrombectomy system for peripheral vascular applications. It is used to remove blood clots from arteries and veins outside of the brain. Market share for Penumbra is estimated to be 20%. Competitors are Boston Scientific and Philips.
- Lightning Flash: Computer-assisted vacuum thrombectomy system to remove fluid and blood clots. Revenue is not reported separately, but contributes substantially to the peripheral business. Major competitor is Inari Medical.
Market Dynamics
Industry Overview
The neurovascular and peripheral vascular markets are experiencing growth due to aging populations and advancements in minimally invasive procedures. These markets are characterized by technological innovation and competition among medical device companies.
Positioning
Penumbra is positioned as an innovator in aspiration and mechanical thrombectomy. They have a strong reputation for developing effective solutions for complex vascular conditions.
Total Addressable Market (TAM)
The combined TAM for neurovascular and peripheral vascular devices is estimated to be tens of billions of dollars globally. Penumbra is positioned to capture a larger share through continued innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong reputation among physicians
- Established distribution network
- Focus on minimally invasive procedures
Weaknesses
- Past product recalls impacted reputation
- Reliance on a limited number of key products
- Susceptible to regulatory scrutiny
- Requires further product development to be a long term player.
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing products
- Acquiring complementary technologies
- Collaborating with research institutions
Threats
- Increasing competition from established players
- Pricing pressures from healthcare providers
- Potential for product liability claims
- Regulatory changes impacting product approval
Competitors and Market Share
Key Competitors
- MDT
- STRY
- BSX
- INMD
Competitive Landscape
Penumbra's competitive advantage lies in its focus on minimally invasive neurovascular and peripheral vascular procedures. However, it faces significant competition from larger, more diversified medical device companies.
Growth Trajectory and Initiatives
Historical Growth: Analysis requires historical financial data.
Future Projections: Analyst estimates are required to provide projections.
Recent Initiatives: Requires specific initiatives to be listed.
Summary
Penumbra is an innovative medical device company with a strong position in the neurovascular and peripheral vascular markets. It boasts a leading aspiration-based thrombectomy device. Recalls and competition are a challenge. Future expansion and strategic acquisitions will drive further growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are based on available data and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Penumbra Inc
Exchange NYSE | Headquaters Alameda, CA, United States | ||
IPO Launch date 2015-09-18 | Co-Founder, Chairman, President & CEO Mr. Adam Elsesser J.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4500 | Website https://www.penumbrainc.com |
Full time employees 4500 | Website https://www.penumbrainc.com | ||
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.